HIGHTIDE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.68 HKD | -5.64% |
|
-13.21% | -71.60% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 6,064 | 1,866 | - | - |
| Enterprise Value (EV) 1 | 5,472 | 1,608 | 2,031 | 3,035 |
| P/E ratio | -3.25 x | -5.85 x | -5.13 x | -6.47 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | 622,140 x |
| EV / Revenue | - | - | - | 1,011,632 x |
| EV / EBITDA | -12.2 x | -5.2 x | -5.98 x | -13.5 x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | 8.6 x | 4.86 x | 92.6 x | -6.96 x |
| Nbr of stocks (in thousands) | 514,771 | 514,771 | - | - |
| Reference price 2 | 11.78 | 3.626 | 3.626 | 3.626 |
| Announcement Date | 24-03-27 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales | - | - | - | 3,000 |
| EBITDA 1 | -447.7 | -309.1 | -339.6 | -224.2 |
| EBIT 1 | -448.2 | -313.8 | -345.1 | -240 |
| Operating Margin | - | - | - | -8% |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income | - | - | - | - |
| Net margin | - | - | - | - |
| EPS 2 | -3.620 | -0.6198 | -0.7064 | -0.5604 |
| Free Cash Flow | - | - | - | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share 2 | - | - | - | - |
| Announcement Date | 24-03-27 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt 1 | - | - | 164 | 1,168 |
| Net Cash position 1 | 592 | 259 | - | - |
| Leverage (Debt/EBITDA) | - | - | -0.484 x | -5.212 x |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets | - | - | - | - |
| Book Value Per Share 2 | 1.370 | 0.7500 | 0.0400 | -0.5200 |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | 0.8 | 9.16 | 54.2 | 454 |
| Capex / Sales | - | - | - | 15.14% |
| Announcement Date | 24-03-27 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.626
CNY
Average target price
6.97
CNY
Spread / Average Target
+92.24%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -71.60% | 257M | |
| +14.84% | 121B | |
| +18.31% | 112B | |
| +4.45% | 22.57B | |
| -18.26% | 20.82B | |
| -16.75% | 16.19B | |
| -42.36% | 16.17B | |
| -14.23% | 16.3B | |
| -0.68% | 13.17B | |
| +21.87% | 11.11B |
- Stock Market
- Equities
- 2511 Stock
- Financials HighTide Therapeutics, Inc.
